肾癌患者术后化疗联合DC-CIK免疫治疗临床疗效研究  

The clinical effects of chemotherapy combined with DC-CIK cells treatment after curative resection for renal cell carcinoma

作　　者：黄焱[1] 穆中一[1] 林洪丽[2] 赵萍[3] 李刚[1] 刘世博[1] 付成[1] 胡滨[1] 

机构地区：[1]辽宁省肿瘤医院(中国医科大学肿瘤医院)泌尿外科,沈阳110042 [2]大连医科大学附属第一医院肾内科 [3]沈阳体育学院门诊部

出　　处：《临床军医杂志》2016年第1期7-10,13,共5页Clinical Journal of Medical Officers

基　　金：辽宁省科技厅科学计划项目(2011225013)

摘　　要：目的评价肾癌患者术后化疗联合自体树突状细胞(DC)联合细胞因子诱导的杀伤(CIK)治疗的临床疗效和安全性。方法收集2007年1月至2010年7月在辽宁省肿瘤医院45例肾癌化疗联合DC-CIK治疗的患者(化疗联合DC-CIK治疗组)及同期对照30例单纯化疗的肾癌患者(单纯化疗组),比较两组患者临床疗效、不良反应以及生存差异,并对外周血淋巴细胞亚群和细胞因子水平进行检测,比较组间差异。结果化疗联合DC-CIK治疗组实体瘤近期缓解情况显著优于化疗组;与治疗前比较,化疗与DC-CIK细胞免疫联合治疗的患者外周血淋巴细胞亚群中CD3^+CD4^+CD8^+、CD3^+CD16^+CD56^+T细胞计数增加(P<0.05);化疗联合CIK治疗组患者的总生存时间(OS)为64个月,明显高于单纯化疗组的45个月(P<0.05)。治疗过程中患者均未出现发热和寒颤等相关不良反应。结论自体DC-CIK细胞回输在联合化疗的基础上治疗晚期肾癌更有生存优势,而且安全性及耐受性良好。Objective To evaluate the safety and therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells（ DC-CIK） combined with chemotherapy in advanced renal cell carcinoma patients. Methods A total of 45 renal cell carcinoma patients treated with chemotherapy combined with DC-CIK（ chemotherapy combined with DC-CIK group） and 30 patients treated with chemotherapy（ chemotherapy-only group） were included in this study（ from January 2007 to July 2013 in Liaoning Cancer Hospital Institute）. The long-term survival,clinical efficacy and adverse reactions were compared between the two groups. The levels of peripheral blood lymphocyte subsets of the two groups were detected and compared. Results The solid tumor remission in the chemotherapy combined with DC-CIK group was better than those of the chemotherapy group. The percentages of CD3~＋CD4~＋CD8~＋,CD3~＋CD16~＋CD56~＋T cells of the chemotherapy combined with DC-CIK group were higher than that of the chemotherapy group. The median overall survival（ OS） of chemotherapy combined with DC-CIK group was 96 months,which was longer than that of 32 months in the chemotherapy group. No evident adverse events were observed. Conclusion Autologous DC-CIK infusion combined with chemotherapy has better efficacy in OS with safety and tolerability for patients with renal cell carcinoma.

关 键 词：肾癌 细胞免疫治疗 树突状细胞 细胞因子诱导的杀伤细胞 临床疗效 

分 类 号：R737.11[医药卫生—肿瘤]